Skip to main content
TipRanks
Go Ultimate75% OFF

PTC Therapeutics (P91) Stock Price & Analysis

1 Followers

P91 Stock Chart & Stats

No data to display
Day’s Range
N/A
52-Week Range
N/A
Previous Close
N/A
Volume
N/A
Average Volume (3M)
N/A
Market Cap
CHF 4.28B
Enterprise Value
CHF 3.92B
Total Cash (Recent Filing)
CHF 2.13B
Total Debt (Recent Filing)
CHF 636.03M
Price to Earnings (P/E)
―
Beta
N/A
Next Earnings
Feb 23, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Sephience Commercial Traction

Sephience is demonstrating meaningful early adoption across U.S. and international markets, supported by sequential revenue growth and a rising active-patient base. Continued penetration of therapy-naive patients, Kuvan switchers and underserved PKU populations could provide a durable commercial growth platform.

Revenue Growth And Breakeven Path

Raised guidance and management’s expected 2026 cash flow breakeven indicate improving operating scale and a clearer path toward internally funded growth. If product expansion continues, stronger cash generation could support pipeline investment while reducing dependence on external financing.

Late-Stage Pipeline Expansion

Adding a BLA-stage Fabry gene therapy gives PTC a potentially commercial-stage asset beyond its existing franchises and broadens its rare-disease platform. The one-time treatment model and planned 2027 launch could create a new growth avenue if regulatory execution remains successful.

Bears Say

Uneven Profitability And Cash Flow

Recent cash generation has not yet proven durable because strong 2025 results were followed by only slightly positive operating cash flow and negative free cash flow on a TTM basis. Continued volatility could limit funding flexibility and make the profitability recovery harder to sustain.

Historical Negative Equity

The history of negative equity signals that PTC has operated with a weak capital structure through several years, even though the latest TTM position has improved. This legacy reduces balance-sheet resilience and leaves less margin for error if operating performance weakens again.

Generic Pressure On Emflaza

Increasing generic competition can structurally erode Emflaza pricing and contribution, reducing the durability of revenue from an established DMD product. The pressure may also shift the portfolio’s dependence toward successful Sephience expansion and new pipeline launches.

PTC Therapeutics News

P91 FAQ

What is PTC Therapeutics’s market cap?
PTC Therapeutics’s market cap is CHF4.28B.
When is PTC Therapeutics’s upcoming earnings report date?
PTC Therapeutics’s next earnings report is estimated for Feb 23, 2027 (not yet confirmed), which is in 97 days.
How were PTC Therapeutics’s earnings last quarter?
PTC Therapeutics released its earnings results on Oct 29, 2026. The company reported -CHF0.508 earnings per share for the quarter, missing the consensus estimate of CHF0.117 by -CHF0.625.
Is PTC Therapeutics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does PTC Therapeutics pay dividends?
PTC Therapeutics does not currently pay dividends.
What is PTC Therapeutics’s EPS estimate?
PTC Therapeutics’s EPS estimate is 0.28.
What happened to PTC Therapeutics’s price movement after its last earnings report?
PTC Therapeutics reported an EPS of -CHF0.508 in its last earnings report, missing expectations of CHF0.117. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of PTC Therapeutics?
Hedge funds hold PTC Therapeutics shares: the largest hedge-fund position in PTC Therapeutics is 1,497,753,356 shares, and hedge funds decreased their holdings by 347.4K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology